Hoechst Marion Roussel to share P&G's Actonel development and marketing for osteoporosis.
HOECHST MARION ROUSSEL TO PROMOTE P&G's ACTONEL (RISEDRONATE) under an agreement announced May 5. Hoechst will collaborate on final development of the osteoporosis and bone disorder agent and will help to market the drug in all countries except Japan. Procter & Gamble will receive milestone payments to offset development costs thus far for risedronate, the companies said. The two companies will share future expenses and revenues.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth